A Phase 2b, Multi-center, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets on HbA1c in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2016
At a glance
- Drugs Bexagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Theracos
- 10 Jun 2017 Biomarkers information updated
- 12 Jul 2016 Status changed from active, no longer recruiting to completed.
- 19 Feb 2016 Planned primary completion date changed from 1 May 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.